Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

被引:4119
作者
Freeman, GJ
Long, AJ
Iwai, Y
Bourque, K
Chernova, T
Nishimura, H
Fitz, LJ
Malenkovich, N
Okazaki, T
Byrne, MC
Horton, HF
Fouser, L
Carter, L
Ling, V
Bowman, MR
Carreno, BM
Collins, M
Wood, CR
Honjo, T [1 ]
机构
[1] Kyoto Univ, Dept Med Chem, Grad Sch Med, Kyoto 6068501, Japan
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[3] Wyeth Ayerst Res, Inst Genet, Cambridge, MA 02140 USA
关键词
binding; proliferation inhibition; cytokine secretion inhibition; tissue expression; peripheral tolerance;
D O I
10.1084/jem.192.7.1027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells. Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features. We report here that the ligand of PD-1 (PD-LI) is a member of the B7 gene family. Engagement of PD-1 by PD-L1 leads to the inhibition of T cell rcceptor-mediated lymphocyte proliferation and cytokine secretion. In addition, PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon gamma, and activated human and murine dendritic cells. In addition, PD-L1 is expressed in nonlymphoid tissues such as heart and lung. The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may determine the extent of T cell activation and consequently the threshold between tolerance and autoimmunity. PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently determine the extent of immune responses at sites of inflammation.
引用
收藏
页码:1027 / 1034
页数:8
相关论文
共 28 条
  • [1] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
    Agata, Y
    Kawasaki, A
    Nishimura, H
    Ishida, Y
    Tsubata, T
    Yagita, H
    Honjo, T
    [J]. INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) : 765 - 772
  • [2] Blair PJ, 1998, J IMMUNOL, V160, P12
  • [3] The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
    Boussiotis, VA
    Freeman, GJ
    Gribben, JG
    Nadler, LM
    [J]. IMMUNOLOGICAL REVIEWS, 1996, 153 : 5 - 26
  • [4] BYRNE MC, 2000, CURRENT PROTOCOLS MO, V49
  • [5] Dong HD, 1999, NAT MED, V5, P1365
  • [6] Characterization of murine Flt4 ligand VEGF-C
    Fitz, LJ
    Morris, JC
    Towler, P
    Long, A
    Burgess, P
    Greco, R
    Wang, J
    Gassaway, R
    Nickbarg, E
    Kovacic, S
    Ciarletta, A
    Giannotti, J
    Finnerty, H
    Zollner, R
    Beier, DR
    Leak, LV
    Turner, KJ
    Wood, CR
    [J]. ONCOGENE, 1997, 15 (05) : 613 - 618
  • [7] SELECTIVE INDUCTION OF B7/BB-1 ON INTERFERON-GAMMA STIMULATED MONOCYTES - A POTENTIAL MECHANISM FOR AMPLIFICATION OF T-CELL ACTIVATION THROUGH THE CD28 PATHWAY
    FREEDMAN, AS
    FREEMAN, GJ
    RHYNHART, K
    NADLER, LM
    [J]. CELLULAR IMMUNOLOGY, 1991, 137 (02) : 429 - 437
  • [8] Freeman GJ, 1998, J IMMUNOL, V161, P2708
  • [9] FREEMAN GJ, 1992, J IMMUNOL, V149, P3795
  • [10] HARPER K, 1991, J IMMUNOL, V147, P1037